#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening


New Features in Screening of Retinopathy of Prematurity. Our Experience with New Recommendations for Retinopathy of Prematurity Screening

Retinopathy of prematurity (ROP) is always a serious and sight-threatening condition, and its treatable stages require early detection and adequate treatment. It is necessary to focus on the principles of screening of ROP and recurrences thereof, which occur more often with the onset of intravitreal treatment using anti-vascular endothelial growth factor (anti-VEGF) agents. In this study, we evaluate the recurrence of ROP after primary treatment with intravitreally administered bevacizumab or ranibizumab, its frequency and timing of occurrence. Also discussed are the rules for screening of ROP, its recurrence and the need for long-term follow-up monitoring of children with any form of ROP.

Keywords:

recurrence of ROP – ROP recurrence screening – intravitreal treatment of ROP – follow-up monitoring of premature infants with ROP – ROP screening


Autoři: Dana Tomčíková;  Zuzana Prepiaková;  Beáta Bušányová;  Barbora Kostolná
Působiště autorů: University and the National Institute of Children’s Diseases, Bratislava, Slovakia ;  Department of Pediatric Ophthalmology, Faculty of Medicine of Comenius
Vyšlo v časopise: Čes. a slov. Oftal., 81, 2025, No. Ahead of Print, p. 1-5
Kategorie: Původní práce
doi: https://doi.org/10.31348/2025/23

Souhrn

Retinopathy of prematurity (ROP) is always a serious and sight-threatening condition, and its treatable stages require early detection and adequate treatment. It is necessary to focus on the principles of screening of ROP and recurrences thereof, which occur more often with the onset of intravitreal treatment using anti-vascular endothelial growth factor (anti-VEGF) agents. In this study, we evaluate the recurrence of ROP after primary treatment with intravitreally administered bevacizumab or ranibizumab, its frequency and timing of occurrence. Also discussed are the rules for screening of ROP, its recurrence and the need for long-term follow-up monitoring of children with any form of ROP.

Stránka

Štítky
Oftalmologie

Článek vyšel v časopise

Česká a slovenská oftalmologie

Číslo Ahead of Print

2025 Číslo Ahead of Print
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Eozinofilní zánět a remodelace
nový kurz
Autoři: MUDr. Lucie Heribanová

Svět praktické medicíny 1/2025 (znalostní test z časopisu)

Hypertrofická kardiomyopatie: Moderní přístupy v diagnostice a léčbě
Autoři: doc. MUDr. David Zemánek, Ph.D., MUDr. Anna Chaloupka, Ph.D.

Vliv funkčního chrupu na paměť a učení
Autoři: doc. MUDr. Hana Hubálková, Ph.D.

Současné možnosti léčby obezity
Autoři: MUDr. Martin Hrubý

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#